[go: up one dir, main page]

IL158306A0 - Pharmaceutical dosage form of amorphous nelfinavir mesylate - Google Patents

Pharmaceutical dosage form of amorphous nelfinavir mesylate

Info

Publication number
IL158306A0
IL158306A0 IL15830602A IL15830602A IL158306A0 IL 158306 A0 IL158306 A0 IL 158306A0 IL 15830602 A IL15830602 A IL 15830602A IL 15830602 A IL15830602 A IL 15830602A IL 158306 A0 IL158306 A0 IL 158306A0
Authority
IL
Israel
Prior art keywords
dosage form
pharmaceutical dosage
nelfinavir mesylate
amorphous nelfinavir
amorphous
Prior art date
Application number
IL15830602A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL158306A0 publication Critical patent/IL158306A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15830602A 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate IL158306A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number Publication Date
IL158306A0 true IL158306A0 (en) 2004-05-12

Family

ID=23106974

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15830602A IL158306A0 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate
IL158306A IL158306A (en) 2001-05-03 2003-10-08 Pharmacological dosage form of amorphous nilfinaviril amylate

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158306A IL158306A (en) 2001-05-03 2003-10-08 Pharmacological dosage form of amorphous nilfinaviril amylate

Country Status (36)

Country Link
US (1) US7014866B2 (xx)
EP (1) EP1390063B1 (xx)
JP (1) JP4101661B2 (xx)
KR (1) KR100554816B1 (xx)
CN (1) CN1255185C (xx)
AR (1) AR034320A1 (xx)
AT (1) ATE282428T1 (xx)
BG (1) BG108311A (xx)
BR (1) BR0209325A (xx)
CA (1) CA2444116C (xx)
CZ (1) CZ20033211A3 (xx)
DE (1) DE60201988T2 (xx)
EA (1) EA006627B1 (xx)
EC (1) ECSP034827A (xx)
ES (1) ES2231717T3 (xx)
GE (1) GEP20053466B (xx)
GT (1) GT200200079A (xx)
HR (1) HRP20030873B1 (xx)
HU (1) HU229938B1 (xx)
IL (2) IL158306A0 (xx)
IS (1) IS7010A (xx)
JO (1) JO2401B1 (xx)
MA (1) MA27018A1 (xx)
MX (1) MXPA03009971A (xx)
MY (1) MY128509A (xx)
NO (1) NO20034689L (xx)
NZ (1) NZ528689A (xx)
PA (1) PA8544501A1 (xx)
PE (1) PE20021159A1 (xx)
PL (1) PL366998A1 (xx)
PT (1) PT1390063E (xx)
RS (1) RS83503A (xx)
SK (1) SK14572003A3 (xx)
TW (1) TWI234461B (xx)
UA (1) UA76463C2 (xx)
WO (1) WO2002089835A2 (xx)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
EP1652525A4 (en) * 2003-07-15 2008-10-01 Arigen Inc ANTI-VIRUS CORONA DRUG
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
MX2007006635A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
DE602006011485D1 (de) * 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
PT1962808E (pt) * 2005-12-14 2010-10-29 Hoffmann La Roche Formulação de precursor de fármaco para o hcv
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
CL2007002331A1 (es) * 2006-08-10 2008-04-18 Cipla Ltd Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih.
JP5546860B2 (ja) 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
CA2686545C (en) * 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
WO2008133949A1 (en) 2007-04-25 2008-11-06 Concert Pharmaceuticals, Inc. Analogues of cilostazol
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
EP2357183B1 (en) 2007-05-01 2015-07-01 Concert Pharmaceuticals Inc. Morphinan compounds
DK2522667T3 (da) 2007-05-01 2014-11-03 Concert Pharmaceuticals Inc Morphinanforbindelser
EP2150525A1 (en) * 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
JP5567503B2 (ja) 2008-02-29 2014-08-06 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
MX2011002994A (es) 2008-09-19 2011-05-30 Concert Pharmaceuticals Inc Compuestos de morfinan.
HUE028956T2 (en) 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
EP2542534A1 (en) 2010-03-02 2013-01-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP2579858B1 (en) 2010-06-14 2014-05-21 Ratiopharm GmbH Ivabradine-containing pharmaceutical composition
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (en) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
MX349159B (es) 2011-05-18 2017-07-14 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor.
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
PT3882249T (pt) 2012-06-15 2025-08-06 Sun Pharmaceutical Ind Inc Derivados deuterados de ruxolitinib
WO2014012009A1 (en) 2012-07-12 2014-01-16 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
EA032094B1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
EP3021861A1 (en) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
JP6526060B2 (ja) 2014-02-10 2019-06-05 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロベンゾジアゼピン
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
MA39999A (fr) 2014-06-06 2015-12-10 Res Triangle Inst Agonistes du récepteur de l'apeline (apj) et leurs utilisations
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US20180044375A1 (en) 2015-03-06 2018-02-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
EP3277647A1 (en) 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
JP6849686B2 (ja) 2015-09-21 2021-03-24 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強剤の投与
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
DK3452039T3 (da) 2016-05-04 2024-10-07 Sun Pharmaceutical Ind Inc Behandling af hårtabslidelser med deutererede jakhæmmere
EP3478664B1 (en) 2016-07-04 2020-12-02 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
EP3490538A4 (en) 2016-08-01 2020-03-18 The Brigham and Women's Hospital, Inc. PARTICLES FOR THE DELIVERY OF PROTEINS AND PEPTIDES
WO2018119076A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
CN116854686A (zh) 2017-05-19 2023-10-10 智优有限公司 瑞喹莫德的衍生物
EP3713557B1 (en) 2017-11-22 2025-03-12 Sun Pharmaceutical Industries, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2020210707A1 (en) 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US20230183203A1 (en) 2020-05-27 2023-06-15 The Penn State Research Foundation Antibacterial compounds
MX2023005027A (es) 2020-10-28 2023-07-31 Sun Pharmaceutical Ind Inc Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US20240307401A1 (en) 2021-08-12 2024-09-19 Sun Pharmaceeutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
AU2023265574A1 (en) 2022-05-04 2024-12-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
CA2302275C (en) * 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
PT1227797E (pt) * 1999-11-12 2005-05-31 Abbott Lab Formulacoes farmaceuticas de dispersao solida
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
JP4101661B2 (ja) 2008-06-18
NZ528689A (en) 2005-03-24
JP2004527569A (ja) 2004-09-09
CN1547484A (zh) 2004-11-17
PE20021159A1 (es) 2002-12-20
US20030021840A1 (en) 2003-01-30
WO2002089835A2 (en) 2002-11-14
ATE282428T1 (de) 2004-12-15
PT1390063E (pt) 2005-03-31
MY128509A (en) 2007-02-28
EP1390063A2 (en) 2004-02-25
DE60201988T2 (de) 2005-12-15
CN1255185C (zh) 2006-05-10
EA200301166A1 (ru) 2004-04-29
BR0209325A (pt) 2004-07-20
NO20034689D0 (no) 2003-10-20
HRP20030873A2 (en) 2005-08-31
TWI234461B (en) 2005-06-21
PA8544501A1 (es) 2002-11-18
GEP20053466B (en) 2005-02-25
RS83503A (sr) 2006-10-27
KR100554816B1 (ko) 2006-02-22
US7014866B2 (en) 2006-03-21
CA2444116C (en) 2009-01-20
UA76463C2 (en) 2006-08-15
HU229938B1 (en) 2015-01-28
SK14572003A3 (sk) 2004-12-01
IL158306A (en) 2008-11-03
NO20034689L (no) 2003-10-20
MA27018A1 (fr) 2004-12-20
AR034320A1 (es) 2004-02-18
HK1070285A1 (en) 2005-06-17
PL366998A1 (en) 2005-02-07
HRP20030873B1 (en) 2006-04-30
JO2401B1 (en) 2007-06-17
IS7010A (is) 2003-10-30
BG108311A (bg) 2004-12-30
WO2002089835A3 (en) 2003-05-01
HUP0401238A2 (hu) 2004-12-28
GT200200079A (es) 2002-12-05
DE60201988D1 (de) 2004-12-23
CZ20033211A3 (cs) 2004-09-15
KR20040007523A (ko) 2004-01-24
MXPA03009971A (es) 2004-02-12
EA006627B1 (ru) 2006-02-24
CA2444116A1 (en) 2002-11-14
ECSP034827A (es) 2003-12-24
HUP0401238A3 (en) 2012-09-28
ES2231717T3 (es) 2005-05-16
EP1390063B1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
IL158306A0 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
GB0117618D0 (en) Pharmaceutical dosage form
GB0117619D0 (en) Pharmaceutical dosage form
IL154012A0 (en) Hydrogel-driven drug dosage form
PL356358A1 (en) Solid dosage form of someticone for oral administration
EG23943A (en) Flash-melt oral dosage formulation
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
HUP0302876A3 (en) Pharmaceutical formulation
GB0118689D0 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
HUP0500638A3 (en) Flashmelt oral dosage formulation
IL172890A0 (en) Saquinavir mesylate oral dosage form
PL362701A1 (en) Pharmaceutical tablet comprising paroxetine mesylate
SI1390063T1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
GB0128138D0 (en) Pharmaceutical use
GB0104749D0 (en) Pharmaceutical formulation
IL134581A0 (en) Pharmaceutical dosage form
PL341178A1 (en) Oral pharmaceutical dosage forms
GB0021927D0 (en) Use of pharmaceutical combination
PL373799A1 (en) Flashmelt oral dosage formulation
IL128582A0 (en) Pharmaceutical dosage form
GB0124712D0 (en) Pharmaceutical formulation
GB0014497D0 (en) Oral dosage form
GB0121677D0 (en) Dosage